Plus: Eli Lilly’s obesity pill gets approval, and will take on a rival from Novo Nordisk in the booming GLP-1 drug market. And the Trump Administration is expected to overhaul steel and aluminum tariffs. Luke Vargas hosts.

Sign up for WSJ’s free What’s News newsletter.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.